Tennessee Center for AIDS Research (TN-CFAR) Implementation Science Consultation Hub

田纳西州艾滋病研究中心 (TN-CFAR) 实施科学咨询中心

• 批准号: 10820025
• 负责人: SIMON Alexander MALLAL
• 金额: $ 57.79万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10820025
• 关键词: Acquired Immunodeficiency Syndrome; Address; Area; Caring; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical; Collaborations; Communication; Communities; Consultations; Continuity of Patient Care; Country; County; Data Analyses; Development; Diagnosis; Education; Educational process of instructing; Eligibility Determination; Epidemic; Epidemiology; Equity; Evidence based intervention; Evidence based practice; Fellowship; Funding; Future; Goals; Grant; HIV; HIV diagnosis; Health Services; Knowledge; Lead; Learning; Manuscripts; Measures; Mentors; Mentorship; Methods; Newly Diagnosed; Organizational Culture; Outcome; Patients; Persons; Phase; Population; Populations at Risk; Positioning Attribute; Prevention; Protocols documentation; Provider; Public Health; Research; Research Infrastructure; Research Methodology; Research Personnel; Research Priority; Research Project Grants; Research Training; Self Efficacy; Series; Services; Site; System; Tennessee; Training; Translational Research; United States; United States National Institutes of Health; Universities; Viral; Virus Diseases; Work; antiretroviral therapy; care delivery; community engagement; deprivation; design; epidemic preparedness; experience; health equity; implementation facilitation; implementation fidelity; implementation research; implementation science; implementation strategy; improved; interest; multidisciplinary; online resource; pre-exposure prophylaxis; programs; racism; science education; skills; social health determinants; social stigma; socioeconomics; success; tool; uptake; workforce needs

Project Summary Human Immunodeficiency Virus (HIV) infection remains a significant public health problem in the United States (US). Despite the availability of safe and effective HIV treatment (antiretroviral therapy, ART) and prevention (pre-exposure prophylaxis, PrEP), there remains a significant proportion of people living with diagnosed HIV who have not achieved viral suppression and a significant proportion of people at risk for HIV acquisition who have not accessed PrEP. The Centers for Disease Control and Prevention estimates that there were 30, 635 people newly diagnosed with HIV in the US in 2020, with 51% located in the South. In 2019, only 56.8% had achieved viral suppression. Similarly, among the estimated 1.2 million people in the US eligible for PrEP only about 25% have accessed it. The field of implementation science provides researchers with the critical tools to address this evidence-practice gap. The development of tailored strategies designed facilitate implementation of evidence based practices can address issues with provider knowledge and self-efficacy, facilitate team communication, improve organizational culture, and create streamlined clinical systems that simplify care delivery. However, many HIV health services researchers do not have formal implementation science training or mentorship in this area. For these reasons, the United States EHE Plan and the National Institutes of Health (NIH) have prioritized the training of a multi-disciplinary workforce needed to conduct high-priority HIV research. Therefore, the overarching goal of this proposal is to continue the work of our Tennessee Center for AIDS Research Implementation Science Hub. We plan to continue supporting IS work through the provision of technical assistance, mentorship, education, and consultative services to NIH EHE implementation science awardees. The Tennessee-CFAR is uniquely positioned to serve as an Ending the HIV Epidemic IS Hub for several important reasons. First, the Tennessee Center for AIDS Research (TN-CFAR) is located in the US South, a region of the country disproportionately impacted by a high HIV burden and low numbers of PrEP users, and our team has experience addressing the prevalent social determinants of health that plague the region including racism, stigma, and socioeconomic deprivation. Second, the proposed TN- CFAR IS Hub team brings complementary expertise in implementation science, mixed methods research, epidemiology, clinical HIV care and treatment, health equity, and community engagement needed for success in carrying out HIV implementation science studies. Third, the team has long-standing collaborations with colleagues in Memphis/Shelby County, Tennessee, a Phase I EHE Priority jurisdiction that would facilitate participation in multi-site HIV implementation science hub studies. We expect that TN-CFAR Implementation Science Hub activities will help EHE awardees and their communities in reaching EHE goals through leveraging our unique academic, public health, and community-based partnerships.

项目概要 人类免疫缺陷病毒（HIV）感染仍然是美国的一个重大公共卫生问题 （我们）。尽管有安全有效的艾滋病毒治疗（抗逆转录病毒疗法，ART）和预防 （暴露前预防，PrEP），仍有相当大比例的人被诊断为艾滋病毒感染者 尚未实现病毒抑制的人群以及相当一部分有感染艾滋病毒风险的人群 尚未访问 PrEP。疾病控制与预防中心估计，有 30, 635 2020 年美国新诊断出的艾滋病毒感染者中，51% 位于南方。 2019年，只有56.8%的人有过 达到了病毒抑制的目的。同样，在美国估计有 120 万人仅符合 PrEP 资格 大约 25% 的人访问过它。实施科学领域为研究人员提供了关键工具 解决这一证据与实践之间的差距。制定旨在促进实施的定制战略 基于证据的实践可以解决提供者知识和自我效能的问题，促进团队 沟通、改善组织文化并创建简化护理的精简临床系统 送货。然而，许多艾滋病毒卫生服务研究人员没有接受过正式的实施科学培训 或该领域的指导。由于这些原因，美国 EHE 计划和美国国立卫生研究院 （NIH）已优先培训开展高优先级艾滋病毒研究所需的多学科工作人员 研究。因此，该提案的总体目标是继续我们田纳西州的工作 艾滋病研究实施科学中心中心。我们计划通过以下方式继续支持 IS 工作 向 NIH EHE 提供技术援助、指导、教育和咨询服务 实施科学奖获得者。田纳西州 CFAR 具有独特的定位，可作为终结艾滋病毒的目标 流行病是中心有几个重要原因。首先，田纳西州艾滋病研究中心 (TN-CFAR) 位于美国南部，该地区受艾滋病毒负担高且艾滋病毒感染率低的影响尤为严重。 PrEP 用户数量，我们的团队拥有解决普遍存在的健康社会决定因素的经验 困扰该地区的问题包括种族主义、耻辱和社会经济剥夺。其次，提出的TN- CFAR IS Hub 团队带来了实施科学、混合方法研究、 成功所需的流行病学、临床艾滋病毒护理和治疗、健康公平以及社区参与 开展艾滋病毒实施科学研究。第三，团队与 田纳西州孟菲斯/谢尔比县的同事，这是第一阶段 EHE 优先管辖区，将促进 参与多地点艾滋病毒实施科学中心研究。我们预计 TN-CFAR 实施 科学中心活动将帮助 EHE 获奖者及其社区通过以下方式实现 EHE 目标： 利用我们独特的学术、公共卫生和社区合作伙伴关系。

项目成果

Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2.

抗体依赖性细胞毒性由 6F5 的未突变共同祖先维持，6F5 是一种利用重链 VH1-2 的 Gp41 构象表位靶向抗体。

• 发表时间: 2022-07-29
• 影响因子: 5.5
• 作者: Wrotniak, Brian H;Garrett, Meghan;Baron, Sarah;Sojar, Hakimuddin;Shon, Alyssa;Asiago;Yager, Jessica;Kalams, Spyros;Croix, Michael;Hicar, Mark D
• 通讯作者: Hicar, Mark D

The Effects of Perceived Stress and Cortisol Concentration on Antiretroviral Adherence When Mediated by Psychological Flexibility Among Southern Black Men Living with HIV.

南方黑人艾滋病毒感染者的心理灵活性介导感知压力和皮质醇浓度对抗逆转录病毒治疗依从性的影响。

• 发表时间: 2021-02
• 影响因子: 4.4
• 作者: Cooper, Robert L;Brown, Lauren L;Tabatabai, Mohammad;Haas, David W;Shepherd, Bryan E;Myers, Hector F;Edgerton, Ryan D;Bonny, Castro;Watson, Julia A;Berthaud, Vladimir
• 通讯作者: Berthaud, Vladimir

Assessment of Risk Factors and Outcomes of Severe Ehrlichiosis Infection.

严重埃利希体病感染的危险因素和结果评估。

• 发表时间: 2020-11-02
• 影响因子: 13.8
• 作者: Kuriakose, Kevin;Pettit, April C;Schmitz, Jonathan;Moncayo, Abelardo;Bloch, Karen C
• 通讯作者: Bloch, Karen C

Endothelial dysfunction and body mass index: is there a role for plasma peroxynitrite?

内皮功能障碍和体重指数：血浆过氧亚硝酸盐有作用吗？

• 发表时间: 2021
• 作者: Chikopela, Theresa;Heimburger, Douglas C;Kaluba, Longa;Hamambulu, Pharaoh;Simfukwe, Newton;Mutale, Wilbroad;Koethe, John R;Goma, Fastone
• 通讯作者: Goma, Fastone

Periodontal Treatment Reduces Circulating Pro-Inflammatory Cytokine and Chemokine Levels in African American HIV+ Individuals with Virological Suppression.

牙周治疗可降低病毒学抑制的非裔美国艾滋病毒个体循环促炎细胞因子和趋化因子水平。

• 发表时间: 2022
• 作者: Sampath, C;Harris, E P;Berthaud, V;Tabatabai, M A;Wilus, D M;Crayton, M A;Moss, K;Webster;Southerland, J H;Koethe, J R;Gangula, P R
• 通讯作者: Gangula, P R